Results 141 to 150 of about 9,786 (244)

Inflammation and oxidant-stress in -thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial

, 2008
P. B. Walter, Eric A. Macklin, John B. Porter, Patricia Evans, Janet L. Kwiatkowski, Ellis J. Neufeld, Thomas D. Coates, Patricia J. Giardina, Elliott Vichinsky, Nancy F. Olivieri, Daniele Alberti, Jaymes Holland, Paul Harmatz   +12 more
openalex   +2 more sources

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox [PDF]

, 2011
Alessia Pepe, Antonella Meloni, Giuseppe Rossi, Maria Chiara Dell’Amico, Domenico Giuseppe D’Ascola, Marcello Capra, Aldo Filosa, Paolo Cianciulli, Cristina Salvatori, Gennaro Restaino, Caterina Borgna‐Pignatti, Massimo Lombardi   +11 more
openalex   +1 more source

Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe Zygomycosis

, 2008
Alexis Soummer, Armelle Mathonnet, Olivier Scatton, P.-P. Massault, A. Paugam, Virginie Lemiale, Jean Paul Mira, Éric Dannaoui, Alain Cariou, Olivier Lortholary   +9 more
openalex   +1 more source

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo [PDF]

, 2016

core   +1 more source

Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients [PDF]

, 2013
Alì Taher, John B. Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakaş, Tomasz Lawniczek, Dany Habr, Jacqueline Ros, Yiyun Zhang, Maria Domenica Cappellini   +13 more
openalex   +1 more source

PSY35 PERSISTENCE AND COMPLIANCE OF DEFEROXAMINE VERSUS DEFERASIROX IN MEDICAID PATIENTS WITH SICKLE-CELL DISEASE (SCD)

, 2010
LB Jordan, Francis Vekeman, Anirban Sengupta, Mitra Corral, A. Guo, MS Dun   +5 more
openalex   +1 more source

Identification of deferasirox as a human xanthine oxidase inhibitor. [PDF]

Life Med
Qi Y, He X, Wu X, Zhou T, Liang N, Jiao J, Chen Y, Yuan Y, Zhang Y, Wang Y, Liu Y, Ding Q.   +11 more
europepmc   +1 more source

Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness [PDF]

, 2014
Jessica Cusato, Sarah Allegra, Davide Massano, Silvia De Francia, Antonio Piga, Antonio D’Avolio   +5 more
openalex   +1 more source

Deferasirox for cardiac siderosis in β‐thalassaemia major: a multicentre, open label, prospective study [PDF]

, 2014
Antonio Piga, Filomena Longo, Raffaella Origa, Simona Roggero, Francesco Pinna, Antonietta Zappu, Chiara Castiglioni, Maria Domenica Cappellini   +7 more
openalex   +1 more source

Glycosidase-activated prodrugs of a cytotoxic iron chelator for targeted cancer therapy. [PDF]

RSC Med Chem
Tomar D, Steinbrueck A, Sedgwick AC, Levine MS, Sessler JL, Metzler-Nolte N.   +5 more
europepmc   +1 more source